Neoadjuvant score in locally advanced rectal cancer: integrating downstaging in risk assessment and looking for new valuable end points

Ann Oncol. 2018 Jul 1;29(7):1493-1494. doi: 10.1093/annonc/mdy182.

Authors

S Roselló¹, A Cervantes²

Affiliations

¹ CIBERONC, Department of Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
² CIBERONC, Department of Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain. Electronic address: [email protected].

PMID: 29767693
DOI: 10.1093/annonc/mdy182

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Disease-Free Survival
Humans
Neoadjuvant Therapy*
Rectal Neoplasms*
Rectum
Risk Assessment